Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
| ▸ | MC3R | P41968 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952343 | 0.90 | L3MBTL1 (0.49) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL12482320 | 0.87 | SMN1; SMN2 (0.48) | TACR1CYP2C19HSD11B1 | |
| SCHEMBL12483003 | 0.85 | TACR1 (0.45) | TACR1CYP2C19HSD11B1MC4RMC3R | |
| SCHEMBL18862951 | 0.83 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1R | |
| SCHEMBL18862950 | 0.83 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1R | |
| SCHEMBL29187960 | 0.82 | TACR1 (0.52) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL28169013 | 0.82 | TACR3 (0.50) | CYP2C9CYP2C19HTR2BMAPK14MEN1 | |
| SCHEMBL13722390 | 0.82 | TACR1 (0.46) | TACR1HSD11B1MC4RMC3RMC1R | |
| Hydrochloric Acid SCHEMBL5811944 | 0.82 | TACR1 (0.42) | TACR1HSD11B1 | |
| SCHEMBL7854892 | 0.81 | TACR1 (0.63) | TACR1HSD11B1MC4RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1667976-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7741322-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1667976-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060281743-A1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | disclosed |
| EP-1667976-A1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030726-A1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | TACR1 4613/4885CYP2C9 1687/4885CYP2C19 632/4885 |
| US-20060281743-A1 | Isoquinolinone potassium channel inhibitors | KCNJ2, KCNQ1, KCNQ2 | TACR1 1839/4885CYP2C9 2418/4885CYP2C19 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.